Gastrointestinal Cancer News

First-line nivolumab plus standard of care chemotherapy failed to prolong 1-year PFS among patients with metastatic colorectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Lenvatinib plus transarterial chemoembolization prolonged survival and improved response rates among patients in China with advanced hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Individuals aged between 20 and 39 years had the greatest burden of distant early-onset colorectal adenocarcinoma, according to a retrospective study published in Cancer Epidemiology, Biomarkers & Prevention.

The FDA granted orphan drug designation to silmitasertib for treatment of biliary tract cancer.

The benefit of immune checkpoint inhibitor therapy for hepatocellular carcinoma did not vary by underlying liver disease, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Adjuvant S-1 therapy significantly extended survival compared with surgery alone among patients with resected biliary tract cancer, according to results of a study conducted in Japan and presented at ASCO Gastrointestinal Cancers Symposium.

A study of eryaspase added to chemotherapy did not meet its primary endpoint of improved OS among patients with advanced pancreatic cancer, according to a presentation at ASCO Gastrointestinal Cancers Symposium.

Use of beta blockers did not affect outcomes among patients treated with immunotherapy for unresectable hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

A three-drug combination demonstrated activity for patients with microsatellite-stable, BRAF V600E-positive metastatic colorectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

The FDA granted orphan drug designation to MT-601, an investigational T-cell immunotherapy, for treatment of advanced or metastatic pancreatic adenocarcinoma.